Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial

British Journal of Cancer · Available online 8 Jul 2026 · In press · DOI 10.1038/s41416-026-03535-6

Free full text

Authors (28)

Katrin M. Sjoquist, Alexander Dobrovic, Kristy P. Robledo, Ksenija Nesic, Sally Baron-Hay, Sumitra Ananda, Nicole McCarthy, Jeffrey Goh, Christopher Steer, Nick Murray, Sonia Yip, Linda R. Mileshkin, J. Lynn Fink, Garry Chang, Lisa Bailey, Yvonne Lee, Danka S. Zebic, U. G. Imalki U. Kariyawasam, Kristy Shield-Artin, Andrew Jarratt, Justin Bedő, Anthony T. Papenfuss, Olga Kondrashova, Matthew Wakefield, Cassandra J. Vandenberg, Martin R. Stockler, Clare L. Scott, Paul M. Waring

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Sjoquist, K., Dobrovic, A., Robledo, K., et al. (2026). Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03535-6

Related articles